FDA clears Editas to test gene-editing drug in humans

The FDA has signed off on Cambridge startup Editas Medicine's plans to launch its first-ever clinical trial, which will make it among the first U.S. companies to test the gene editing technology CRISPR/Cas9 in humans. Editas (Nasdaq: EDIT) said Friday that the FDA had approved the launch of an early-stage trial of its drug for the most common cause of childhood blindness. The treatment uses CRISPR/Cas9, which allows scientists to replace or eliminate disease-causing segments of DNA. The study,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news